All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Pain mechanisms in psoriatic arthritis
By Ella Dixon
Featured
At the European Alliance of Associations for Rheumatology (EULAR) Congress 2024, our Steering Committee member Peter Nash, Griffith University, Queensland, AU, interviewed Kurt De Vlam, KU Leuven, Leuven, BE about his current work in psoriatic arthritis (PsA).
Pain mechanisms in psoriatic arthritis
De Vlam explains his research on metabolic profiling in PsA, particularly the role of lipids in disease initiation. He then focuses on his studies exploring different types of pain mechanisms in PsA, highlighting how a greater understanding of this might influence treatment selection. Finally, De Vlam discusses the role of Janus kinase (JAK) inhibitors in the treatment of PsA, especially in patients with higher pain levels.
More about...
Your opinion matters
10 votes - 50 days left ...
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox